Saturday 17 October 2026
Export SPRO’s income statement to Excel — free account
Spero Therapeutics, Inc.
SPRO Healthcare Biotechnology
Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 95.6%, EPS fell 433.3% and free cash flow grew 69.7%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
1.10
0.03
−2.65%
Follow SPRO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
15.53 | 0.00 | 3.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 2 | 4 | 4 | 4 | 2 | 3 | 3 | — | — |
P/S ratio |
1.95 | 1.16 | 0.77 | 1.22 | 27.09 | 46.52 | 9.63 | 24.81 | 15.87 | 0.00 |
Altman Z-Score |
1.04 | (6.43) | (0.81) | (3.65) | (0.04) | 8.97 | (0.33) | 2.96 | 0.31 | — |
Altman Z″-Score (non-manufacturers) |
(8.90) | (13.81) | (1.33) | (6.62) | (4.00) | 2.45 | (3.40) | 9.21 | 9.98 | (23.71) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(15.63) | (2.38) | (4.58) | 1.47 | (18.09) | (26.49) | (10.06) | (7.28) | (2.47) | (0.37) |
Beneish M-Score |
(1.00) | (4.29) | 21.97 | (3.03) | (3.17) | (2.40) | 1.95 | (0.47) | 2.44 | — |
P/B ratio |
2.21 | 1.21 | 0.75 | 0.86 | 5.60 | 3.29 | 2.34 | 0.85 | 0.37 | 0.00 |
Price to Tangible BV |
2.21 | 1.21 | 0.75 | 0.86 | 5.60 | 3.29 | 2.34 | 0.85 | 0.37 | 0.00 |
EV/Sales |
1.35 | 0.06 | 0.04 | (0.82) | 19.08 | 32.92 | 5.11 | (4.29) | (28.24) | 0.00 |
EV/EBITDA |
14.30 | 0.00 | 0.17 | 1.06 | 0.00 | 0.00 | 0.00 | 0.40 | 1.35 | 0.61 |
EV/Operating CF |
(7.15) | (0.12) | (0.11) | 5.65 | (5.41) | (3.58) | (1.85) | 0.43 | 1.43 | 0.61 |
EV/FCF |
(7.13) | (0.12) | (0.11) | 5.63 | (5.41) | (3.57) | (1.84) | 0.40 | 1.39 | 0.61 |
Quick Ratio |
7.40 | 2.15 | 3.42 | 5.09 | 7.98 | 9.28 | 3.40 | 9.48 | 11.06 | 1.54 |
Current Ratio |
7.59 | 2.19 | 3.53 | 5.25 | 8.46 | 9.70 | 3.58 | 10.08 | 11.29 | 1.72 |
Net Debt/EBITDA |
(6.38) | 0.72 | (3.49) | 2.64 | 1.68 | 1.62 | 1.31 | 2.72 | 2.11 | 0.31 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.74 | 0.33 | 0.68 | 0.36 | 0.11 | 0.07 | 0.15 | 0.04 | 0.04 | 0.05 |
Operating CF/Net income |
(1.47) | 0.34 | (1.45) | 0.17 | 0.72 | 1.09 | 0.82 | 0.95 | 0.85 | 0.97 |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | 0.06 | (0.21) | (0.42) | (5.96) | (0.07) | (2.97) |
Interest Coverage |
— | — | — | (16.20) | (45.35) | (197.29) | (47.60) | (37.42) | (137.72) | — |
| 16.31% | (89.62%) | 24.95% | (56.53%) | (81.48%) | (76.31%) | (63.99%) | (41.49%) | (258.18%) | (169.30%) | |
| 9.55% | (46.81%) | 14.85% | (31.37%) | (55.32%) | (60.74%) | (51.83%) | (37.45%) | (85.96%) | (434.62%) | |
ROIC |
21.04% | 0.00% | 43.93% | 0.00% | 0.00% | (963.10%) | 0.00% | (6,493.63%) | 0.00% | 0.00% |
Return on Tangible Assets |
14.67% | (117.81%) | 24.25% | (50.29%) | (64.01%) | (62.33%) | (85.78%) | (36.29%) | (54.19%) | (463.71%) |
Average Days of Receivables |
138.71 | 399.23 | 178.30 | 7.39 | 52.80 | 241.61 | 171.89 | 119.46 | 542.80 | 331.22 |
Research and Development Expense of Revenue |
57.58% | 201.67% | 49.57% | 88.94% | 353.45% | 718.15% | 362.46% | 854.39% | 1,660.89% | 7,860.60% |
Selling, General and Administrative Expense of Revenue |
31.70% | 49.41% | 24.62% | 68.18% | 228.42% | 229.80% | 85.90% | 324.94% | 547.75% | 2,156.12% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6.47% | 16.24% | 7.64% | 17.05% | 51.65% | 52.39% | 20.81% | 69.31% | 72.11% | 53.73% |
Graham Net Nets |
0.44 | 0.77 | 0.70 | 0.99 | 0.15 | 0.27 | 0.37 | 1.13 | 2.66 | 5.11 |
Graham Number |
1.89 | 0.00 | 4.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
6.44% | (123.30%) | 28.29% | (95.40%) | (18.05%) | (18.62%) | (34.30%) | (42.76%) | (710.00%) | (951.57%) |
Free Cash Flow Yield |
(9.70%) | (42.19%) | (41.24%) | (11.88%) | (13.02%) | (19.82%) | (28.81%) | (43.03%) | (128.00%) | (922.37%) |
Revenue per Share |
1.19 | 0.89 | 1.97 | 1.42 | 0.59 | 0.42 | 1.00 | 0.25 | 0.77 | 1.07 |
Operating CF per Share |
(0.23) | (0.43) | (0.63) | (0.21) | (2.08) | (3.84) | (2.75) | (2.48) | (15.12) | (92.76) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | (0.02) | (0.15) | (0.01) | (2.66) |
Free Cash Flow per Share |
(0.23) | (0.43) | (0.63) | (0.21) | (2.08) | (3.84) | (2.77) | (2.63) | (15.13) | (95.42) |
Cash per Share |
0.72 | 0.98 | 1.45 | 2.90 | 4.74 | 5.67 | 4.52 | 7.21 | 33.74 | 33.04 |
Shareholders Equity per Share |
1.05 | 0.85 | 2.03 | 2.02 | 2.86 | 5.90 | 4.11 | 7.24 | 32.84 | 20.37 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.05 | 0.85 | 2.03 | 2.02 | 2.86 | 5.90 | 4.11 | 7.24 | 32.84 | 20.37 |
Free Cash Flow |
(12.62) | (23.44) | (32.99) | (7.73) | (64.31) | (86.03) | (50.33) | (42.06) | (39.14) | (29.79) |
Working Capital |
58.42 | 58.20 | 94.06 | 91.92 | 139.20 | 124.80 | 68.75 | 111.90 | 83.90 | 4.95 |
Capital Expenditures |
— | — | — | — | 0.04 | (0.16) | (0.31) | (2.44) | (0.03) | (0.83) |
Net Current Asset Value |
57.39 | 42.86 | 55.71 | 64.70 | 75.09 | 117.73 | 63.89 | 111.07 | 83.54 | 4.46 |
EV/EBIT |
14.30 | 0.00 | 0.18 | 1.04 | 0.00 | 0.00 | 0.00 | 0.40 | 1.34 | 0.60 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.61 | 0.01 | 2.48 |
Price to Operating Income |
20.67 | 0.00 | 3.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | 0.00 | 183.50 | 2.36 | 0.63 | 0.46 | 0.33 | 0.14 | 0.31 | 0.19 |
Cash ROIC |
(12.71%) | (23.68%) | (18.01%) | (4.18%) | (27.40%) | (33.22%) | (32.14%) | (18.18%) | (22.72%) | (178.63%) |
Accounts Receivable Turnover |
1.72 | 0.93 | 4.01 | 28.73 | 4.14 | 1.27 | 3.69 | 1.87 | 1.22 | 0.21 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
38.93 | 51.59 | 25.89 | 1.86 | 4.41 | 7.36 | 4.92 | 2.12 | 1.62 | 1.62 |
Average Payables |
4.00 | 4.34 | 1.00 | 0.86 | 1.13 | 2.65 | 3.88 | 3.54 | 2.30 | 2.30 |
Average Assets |
89.73 | 146.47 | 153.60 | 147.94 | 162.26 | 129.78 | 117.55 | 111.24 | 53.63 | 6.89 |
Average Common Equity |
52.57 | 76.51 | 91.41 | 82.11 | 110.16 | 103.31 | 95.21 | 100.41 | 17.85 | 17.68 |
Columns are period end dates